Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses

 
• By Mandy Jackson

Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.

3d rendering: Vaccination against new Corona Virus SARS-CoV-2: A glass with vaccination and a syringe behind it. The word vaccination in English, Spanish, French and German on the label. Copy space
Moderna's vaccine generated antibodies that can neutralize SARS-CoV-2 in all 45 Phase I participants • Source: Shutterstock

More from Clinical Trials

More from R&D